OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: NeuroTherapia, Inc.

2 Projects | 2 Researchers | $4,915,725 Invested

2021

NeuroTherapia, Inc.

Tony Giordano, PhD

Multiple Ascending Dose Studies to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Effects of NTRX-07 in Subjects with Early Alzheimer's disease (AD)

  • Funding Amount: $3,250,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Neuroinflammation
  • Status: Active

2015

NeuroTherapia, Inc.

Joseph Foss, MD

Preclinical safety and toxicology of NTRX-07 (formerly MDA7)

  • Funding Amount: $1,665,725
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed